Tandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Purchased by Silvercrest Asset Management Group LLC

Silvercrest Asset Management Group LLC raised its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM - Free Report) by 29.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 346,565 shares of the medical device company's stock after buying an additional 78,347 shares during the quarter. Silvercrest Asset Management Group LLC owned about 0.53% of Tandem Diabetes Care worth $12,483,000 as of its most recent SEC filing.

A number of other large investors have also modified their holdings of the business. Vanguard Group Inc. boosted its position in Tandem Diabetes Care by 1.1% during the fourth quarter. Vanguard Group Inc. now owns 7,440,005 shares of the medical device company's stock worth $267,989,000 after acquiring an additional 77,451 shares during the last quarter. ArrowMark Colorado Holdings LLC lifted its stake in Tandem Diabetes Care by 14.1% in the 4th quarter. ArrowMark Colorado Holdings LLC now owns 2,723,715 shares of the medical device company's stock worth $98,108,000 after purchasing an additional 337,026 shares in the last quarter. GW&K Investment Management LLC lifted its stake in Tandem Diabetes Care by 18.0% in the 4th quarter. GW&K Investment Management LLC now owns 2,123,488 shares of the medical device company's stock worth $76,488,000 after purchasing an additional 323,674 shares in the last quarter. Jacobs Levy Equity Management Inc. boosted its holdings in shares of Tandem Diabetes Care by 189.0% during the 4th quarter. Jacobs Levy Equity Management Inc. now owns 1,661,013 shares of the medical device company's stock worth $59,830,000 after purchasing an additional 1,086,337 shares during the last quarter. Finally, Park West Asset Management LLC grew its position in shares of Tandem Diabetes Care by 49.5% in the fourth quarter. Park West Asset Management LLC now owns 1,600,000 shares of the medical device company's stock valued at $57,632,000 after purchasing an additional 530,000 shares in the last quarter.

Analyst Upgrades and Downgrades

TNDM has been the subject of several recent research reports. Robert W. Baird cut their price target on Tandem Diabetes Care from $33.00 to $24.00 and set a "neutral" rating for the company in a report on Thursday, May 1st. Royal Bank of Canada cut their target price on Tandem Diabetes Care from $65.00 to $55.00 and set an "outperform" rating for the company in a research note on Thursday, February 27th. Piper Sandler reduced their price target on Tandem Diabetes Care from $36.00 to $30.00 and set an "overweight" rating on the stock in a report on Thursday, May 1st. Barclays dropped their price objective on shares of Tandem Diabetes Care from $60.00 to $53.00 and set an "overweight" rating for the company in a report on Friday, February 28th. Finally, Stifel Nicolaus cut their price objective on shares of Tandem Diabetes Care from $60.00 to $31.00 and set a "buy" rating for the company in a research report on Thursday, May 1st. Eight research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care currently has an average rating of "Moderate Buy" and a consensus price target of $37.47.

Tandem Diabetes Care Trading Up 0.0%

TNDM traded up $0.01 on Friday, hitting $20.65. The company had a trading volume of 262,000 shares, compared to its average volume of 1,483,122. The company's fifty day moving average price is $19.38 and its 200 day moving average price is $27.60. Tandem Diabetes Care, Inc. has a 1 year low of $15.75 and a 1 year high of $53.69. The company has a current ratio of 2.90, a quick ratio of 2.32 and a debt-to-equity ratio of 1.29. The firm has a market cap of $1.38 billion, a P/E ratio of -10.72 and a beta of 1.47.

Tandem Diabetes Care (NASDAQ:TNDM - Get Free Report) last announced its quarterly earnings results on Wednesday, April 30th. The medical device company reported ($0.67) earnings per share for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.07). Tandem Diabetes Care had a negative net margin of 14.84% and a negative return on equity of 44.19%. The company had revenue of $234.42 million for the quarter, compared to analyst estimates of $220.19 million. During the same quarter in the prior year, the business earned ($0.65) earnings per share. Tandem Diabetes Care's revenue was up 22.3% on a year-over-year basis. As a group, equities analysts expect that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current year.

Insider Buying and Selling

In other news, COO Jean-Claude Kyrillos acquired 10,538 shares of the business's stock in a transaction that occurred on Friday, March 7th. The shares were purchased at an average price of $18.12 per share, for a total transaction of $190,948.56. Following the acquisition, the chief operating officer now owns 10,538 shares of the company's stock, valued at $190,948.56. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.90% of the stock is currently owned by corporate insiders.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.